X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Natco Pharma with J.B.Chemicals - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NATCO PHARMA vs J.B.CHEMICALS - Comparison Results

J.B.CHEMICALS 
   Change

JB Chemicals and Pharmaceuticals Limited (JBCPL), the flagship of the Unique Group, is one of the India's leading transnational pharmaceutical company. The company has 11 manufacturing facilities at four locations in India (Belapur, Ankleshwar, Panol... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NATCO PHARMA J.B.CHEMICALS NATCO PHARMA/
J.B.CHEMICALS
 
P/E (TTM) x 16.1 17.4 92.8% View Chart
P/BV x 17.4 2.4 739.3% View Chart
Dividend Yield % 0.7 0.2 399.3%  

Financials

 NATCO PHARMA   J.B.CHEMICALS
EQUITY SHARE DATA
    NATCO PHARMA
Mar-14
J.B.CHEMICALS
Mar-16
NATCO PHARMA/
J.B.CHEMICALS
5-Yr Chart
Click to enlarge
High Rs877318 275.7%   
Low Rs424200 212.3%   
Sales per share (Unadj.) Rs223.4148.0 151.0%  
Earnings per share (Unadj.) Rs31.119.1 162.8%  
Cash flow per share (Unadj.) Rs40.323.9 168.2%  
Dividends per share (Unadj.) Rs5.000.50 1,000.0%  
Dividend yield (eoy) %0.80.2 398.0%  
Book value per share (Unadj.) Rs219.5128.9 170.2%  
Shares outstanding (eoy) m33.0784.82 39.0%   
Bonus/Rights/Conversions PA--  
Price / Sales ratio x2.91.7 166.4%   
Avg P/E ratio x20.913.6 154.3%  
P/CF ratio (eoy) x16.110.8 149.4%  
Price / Book Value ratio x3.02.0 147.6%  
Dividend payout %16.12.6 614.3%   
Avg Mkt Cap Rs m21,50421,951 98.0%   
No. of employees `000NA2.7 0.0%   
Total wages/salary Rs m1,1281,841 61.2%   
Avg. sales/employee Rs ThNM4,590.9-  
Avg. wages/employee Rs ThNM673.4-  
Avg. net profit/employee Rs ThNM592.1-  
INCOME DATA
Net Sales Rs m7,38912,551 58.9%  
Other income Rs m167542 30.9%   
Total revenues Rs m7,55613,093 57.7%   
Gross profit Rs m1,7932,055 87.3%  
Depreciation Rs m304412 73.8%   
Interest Rs m36696 382.7%   
Profit before tax Rs m1,2902,088 61.8%   
Minority Interest Rs m460 -11,575.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m309469 65.8%   
Profit after tax Rs m1,0271,619 63.5%  
Gross profit margin %24.316.4 148.3%  
Effective tax rate %23.922.5 106.5%   
Net profit margin %13.912.9 107.8%  
BALANCE SHEET DATA
Current assets Rs m3,6817,778 47.3%   
Current liabilities Rs m3,1234,358 71.7%   
Net working cap to sales %7.627.2 27.7%  
Current ratio x1.21.8 66.1%  
Inventory Days Days8955 163.7%  
Debtors Days Days5980 73.3%  
Net fixed assets Rs m7,6855,713 134.5%   
Share capital Rs m331170 195.0%   
"Free" reserves Rs m6,67010,547 63.2%   
Net worth Rs m7,25910,937 66.4%   
Long term debt Rs m9550-   
Total assets Rs m11,95715,574 76.8%  
Interest coverage x4.522.8 19.8%   
Debt to equity ratio x0.10-  
Sales to assets ratio x0.60.8 76.7%   
Return on assets %11.711.0 105.9%  
Return on equity %14.214.8 95.6%  
Return on capital %20.720.0 103.8%  
Exports to sales %39.448.7 80.8%   
Imports to sales %5.77.1 80.5%   
Exports (fob) Rs m2,9086,115 47.6%   
Imports (cif) Rs m421889 47.4%   
Fx inflow Rs m3,4456,169 55.9%   
Fx outflow Rs m7031,285 54.7%   
Net fx Rs m2,7434,884 56.2%   
CASH FLOW
From Operations Rs m1,4401,397 103.1%  
From Investments Rs m-1,089-320 340.1%  
From Financial Activity Rs m-353-1,196 29.5%  
Net Cashflow Rs m-1-102 1.5%  

Share Holding

Indian Promoters % 52.0 55.4 93.9%  
Foreign collaborators % 1.5 0.3 490.0%  
Indian inst/Mut Fund % 7.8 3.4 231.3%  
FIIs % 16.6 3.9 426.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.0 37.0 70.3%  
Shareholders   25,395 30,437 83.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NATCO PHARMA With:   IPCA LABS  SANOFI INDIA  DR. DATSONS LABS  MERCK LTD  NOVARTIS  

Compare NATCO PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Continue Sell-Off; Sensex Slumps Over 530 Points(Closing)

Share markets in India continued their sell-off seen during the last week and ended the day deep in the red. All sectoral indices traded on a negative note.

Related Views on News

NATCO PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 93.3% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, NATCO PHARMA has posted a net profit of Rs 2 bn (up 93.3% YoY). Sales on the other hand came in at Rs 5 bn (up 21.0% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

NATCO PHARMA Announces Quarterly Results (4QFY18); Net Profit Up 69.6% (Quarterly Result Update)

May 25, 2018 | Updated on May 25, 2018

For the quarter ended March 2018, NATCO PHARMA has posted a net profit of Rs 3 bn (up 69.6% YoY). Sales on the other hand came in at Rs 8 bn (up 32.9% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NATCO PHARMA SHARE PRICE


Sep 24, 2018 (Close)

TRACK NATCO PHARMA

  • Track your investment in NATCO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NATCO PHARMA 5-YR ANALYSIS

COMPARE NATCO PHARMA WITH

MARKET STATS